Lataa...
CCR5 receptor antagonists in preclinical to phase II clinical development for treatment of HIV
INTRODUCTION: The chemokine receptor CCR5 has garnered significant attention in recent years as a target to treat HIV infection largely due to the approval and success of the drug Maraviroc. The side effects and inefficiencies with other first generation agents led to failed clinical trials, prompti...
Tallennettuna:
| Julkaisussa: | Expert Opin Investig Drugs |
|---|---|
| Päätekijät: | , , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
2016
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5776690/ https://ncbi.nlm.nih.gov/pubmed/27791451 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/13543784.2016.1254615 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|